title: Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
abstract: Nab-paclitaxel (Abraxane(®)) is an albumin-bound form of paclitaxel that utilizes the natural properties of albumin to improve paclitaxel delivery to the tumor. It is licensed for use in metastatic breast cancer (MBC) at a dose of 260 mg/m(2) Q3W based on its superior therapeutic index versus conventional paclitaxel 175 mg/m(2) Q3W demonstrated in a Phase III study. In a post-hoc analysis, nab-paclitaxel treatment was associated with rapid and dramatic tumor responses in patients with poor prognostic factors (visceral dominant disease, ≥3 metastatic lesions), suggesting it may be a preferred treatment for these patients. Moreover, significant efficacy has been seen with nab-paclitaxel 100 and 150 mg/m(2) QW 3/4, suggesting it may be possible to tailor use of this agent in the future.
authors.affiliation: Medical Oncology Department, Breast Cancer Unit, Hospital Universitario, Madrid, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Ciruelos
authors.forename: Christian
authors.initials: C
authors.lastname: Jackisch
mesh_terms: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000627:therapeutic use*
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel